Richard R. Kerr
Out-of-pocket infertility costs vary widely
Out-of-pocket costs for couples being treated for infertility range from a low of $912 for medication only to $19,234 for in vitro fertilization (IVF), according to researchers who say their data will help couples plan for the expenses they may incur. The current study is published online in the Journal of Urology ahead of the February 2014 print issue.
Dr. Hopkins, 71, launched Jackson Hole Seminar
Ralph Edward Hopkins, MD, a Riverton, WY urologist who began the Jackson Hole Urological Seminar in 1979, has died. He was 71.
Infused anesthetic reduces post-op pain in children
Researchers have identified a new technique that they say will significantly decrease pain for children following high-risk urologic surgeries.
Infertility out-of-pocket costs vary widely
Out-of-pocket costs for couples being treated for infertility range from a low of $912 for medication only to $19,234 for in vitro fertilization, according to researchers who say their data will help couples plan for the expenses they may incur.
FDA approves drug treatment for Peyronie’s disease
FDA approves drug treatment for Peyronie’s disease
The FDA has approved collagenase clostridium histolyticum (CCH [XIAFLEX]) as the first medication to treat of Peyronie's disease (PD).
Drug combo offers survival benefit in advanced prostate cancer
Men with hormone-sensitive metastatic prostate cancer who received docetaxel (Taxotere) given at the start of standard hormone therapy lived longer than patients who received hormone therapy alone, according to early study results that the lead investigator called “practice changing.”
Payment slide, regs, ACA: Urologists' least-favorite things
Declining reimbursement remains the number one concern of practicing urologists, according to findings from the 8th installment of Urology Times' exclusive State of the Specialty survey.
Program eases surveillance vs. treatment decision
When the pros and cons of prostate cancer treatment are spelled out using an online interactive program, more patients choose active surveillance over definitive treatment, according to researchers from Thomas Jefferson University in Philadelphia who developed the program.
Peyronie’s agent meets phase III study endpoints
Peyronie’s agent meets phase III study endpoints
Data from phase III studies of collagenase clostridium histolyticum (CCH [XIAFLEX]) showed that the agent met primary endpoints related to Peyronie’s disease (PD) curvature and symptoms, and that it is effective and safe in certain subgroups of men with PD, according to Auxilium Pharmaceuticals, Inc.
Post-vasectomy reversal patency possible at 38 years
Contrary to popular belief and scientific predictions, a man’s patency after vasectomy reversal is possible almost 40 years after the original vasectomy, according to a study of more than 1,200 reversals that the authors say is the largest such study ever published.

Poll